Dear Sirs,

Since coronavirus disease 2019 (COVID-19) outbreak, neurologic manifestations have been increasingly reported including encephalopathy; however, the underlying pathophysiology remains mostly unclear \[[@CR1]\]. Neurotropism of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been suspected \[[@CR2]\], though neuropathological studies did not show specific brain changes \[[@CR3]\].

Besides the SARS-CoV-2 infection, a dysregulated immune response resulting in a massive release of proinflammatory cytokines is involved in pathogenesis of severe COVID-19 manifestations and multi-organ failure \[[@CR4]\]. This systemic hyperinflammatory state may be involved in neurologic impairment, as well.

We report a case of COVID-19-related encephalopathy, questioning temporal relations between infection, cytokine storm, and neurologic involvement.

A 77-year-old female, with no history of neurological disease, presented with impaired consciousness after 18-days history of SARS-CoV-2 infection and acute respiratory distress requiring invasive mechanical ventilation (Fig. [1](#Fig1){ref-type="fig"}). Patient was placed on hydroxychloroquine, levofloxacin, and piperacillin/tazobactam.Fig. 1Clinical symptoms, diagnostic work-up, treatment, and inflammatory profile during the disease course. *CSF* cerebrospinal fluid, *ARDS* acute respiratory distress syndrome, *EEG* electroencephalography, *CT* computed tomography, *LP* lumbar puncture, *MRI* magnetic resonance imaging, *FDG-PET* fluorodeoxyglucose-positron emission tomography, *CRP* C-reactive protein, *IL-6* interleukin-6, *IL-8* interleukin-8, *TNFα* tumor necrosis factor-alpha, *IL-12* interleukin-12, *IL-1β* interleukin-1Beta, *IL-10* interleukin-10; \< , under limit of detection. Reference range: CRP \< 0,50 mg/dl; ferritin 11--306 ng/ml; IL-6 \< 5,9 pg/ml; IL-8 \< 70 pg/ml; TNFα \< 8,1 pg/ml, IL-10 \< 9 pg/ml

Despite a remarkable respiratory improvement, at time of first neurologic evaluation, patient presented awake but mutacic, without any goal-directed behavior. No meningeal irritations or focal signs were found. Stimulus-induced myoclonus and positive primitive reflexes (blinking, left grasp) were observed. Electroencephalogram (EEG) recording showed a generalized slowing activity, prevalent in frontal regions. A magnetic resonance imaging (MRI) displayed diffuse white-matter lesions consistent with chronic small vessel disease without contrast enhancement (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Magnetic resonance imaging (MRI), ^18^F-FDG-PET/CT, and electroencephalography (EEG) findings. Normal MRI findings in MRI on T1 with gadolinium (**a**). ^18^F-FDG-PET/CT showing severe frontal lobe hypometabolism (**b**). EEG alterations observed at time of first neurologic evaluation with prominent and bilateral frontal slowing (**c**). Electroencephalographic acquisition settings: 10--20 system, longitudinal montage. Recording speed: 30 s/page; sensitivity: 7 μV/mm; time constant: 0.1 s; high-frequency filter: 70 Hz

Cerebrospinal fluid (CSF) analysis detected normal white blood cell counts and mild increase of the blood--brain barrier permeability (CSF protein = 56 mg/dl, reference range \< 50; CSF/serum albumin ratio = 15,6, reference range \< 7,4).

CSF reverse transcription-PCR (RT-PCR) for SARS-CoV-2 was negative. Additional CSF studies, including oligoclonal bands, neurotropic virus, bacterial cultures, and autoimmune encephalitis antibody panel, were all negative.

Cytokines levels were tested both in CSF and blood documenting a significant increase of interleukin-6 (IL-6) (55.1 and 9.1 pg/ml respectively, reference range \< 5,9) and interleukin-8 (IL-8) (106 and 2721 pg/ml, respectively, reference range \< 70) (Fig. [1](#Fig1){ref-type="fig"}).

^18^F-fluorodeoxyglucose-positron emission tomography (^18^F-FDG-PET/CT) scan showed a spread frontal lobe hypometabolism (Fig. [2](#Fig2){ref-type="fig"}).

She was treated with intravenous methylprednisolone 60 mg for 10 days.

Over time, patient slowly but progressively improved until complete recovery of speech and environment interaction. Serial EEGs showed gradual reduction of previous slow activity. The second lumbar puncture detected a mild increase of blood--brain barrier permeability (CSF protein = 66 mg/dl, reference range \< 50; CSF/serum albumin ratio = 13,7, reference range \< 7,4), but a significant reduction of cytokines levels. CSF RT-PCR for SARS-CoV-2 was still negative.

Neurologic syndrome was characterized by a status of akinetic mutism in keeping with the frontal slowing and hypometabolism shown at EEG and 18F-FDG-PET/CT, respectively. Structural lesions were excluded by brain MRI as well as autoimmune underlying causes by CSF and serum findings. Repeated negative CSF RT-PCR make SARS-Cov-2 neuroinvasion unlikely, although the presence of SARS-CoV-2 in CSF may be transient or untraceable.

Indeed, CSF analysis documented a downward trend of cytokines levels over time, from elevated IL-6 and IL-8 levels to normalization, which closely reflected the clinical improvement, suggesting a possible underlying cytokine-mediated inflammatory process.

In particular, cytokine-mediated endothelial activation and increased brain--blood permeability are related to neurotoxicity \[[@CR5], [@CR6]\].

It is still not clearly understood in SARS-CoV-2 infection whether CSF neuroinflammation and subsequent neurotoxicity are induced by increased serum concentration of cytokines or directly driven by viral endothelial activation and blood--brain barrier disruption.

However, high CSF/serum IL-6 ratio detected in our patient at time of first lumbar puncture suggests that after a primary hit, cell--cytokine relationships may exponentially amplify resulting in intrathecal synthesis of neuroinflammatory mediators and glutamate hyper-excitatory neurotoxicity.

Predominant frontal symptoms with anterior slowing EEG findings and bilateral frontotemporal hypoperfusion have been similarly described in other cases of COVID-19-related encephalopathy \[[@CR1], [@CR7]\]. In our case, ^18^F-FDG-PET study confirmed the prevalent frontal involvement, showing spread frontal lobe hypometabolism.

Frontal syndrome may thus be considered the predominant feature of acute encephalopathy COVID-19-related. Moreover, cross-checked serum and CSF cytokines levels may represent a useful biomarker of early detection and progression of the neurologic involvement, as well as a ground for therapeutic recommendations and prognosis predictions.

Indeed, as the number of patients with COVID-19 increases worldwide, clinicians should be aware of predominant frontal lobe presentation and cytokine-mediated hyperinflammatory process. Further investigation is needed to evaluate efficacy of immunomodulatory therapies and interleukin/interleukin-receptor antagonist in COVID-19-related encephalopathy.
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